Abstract
Perhaps the most important obstacle to the improved survival of cancer patients is disseminated spread of the disease (metastasis), which is the culmination of a complex series of events referred to collectively as the metastatic cascade. During the growth of the initial tumor mass, many cells become detached and migrate into the surrounding normal tissue (invasion). Some tumor cells migrate into the circulatory system (intravasation) and are carried throughout the patient. Once in the circulation, tumor cells can pass freely between the circulatory and lymphatic systems (Hilgard et al. 1972). However, patients having a large population of circulating tumor cells do not necessarily have a poor prognosis (Salsbury 1975), since fewer than 0.001% of the circulating tumor cells are able to attach to the endothelium or subcellular matrix of the vessel wall (arrest and adhesion), migrate into the surrounding tissue (extravasation), and form secondary tumors (Weiss 1980, 1982, 1983). It would therefore appear that the arrest and adhesion steps of the metastatic cascade are critical to the formation of metastases and could be a favorable target for antimetastatic therapy regimens.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Abbreviations
- ADP:
-
adenosine 5′-diphosphate
- MEC:
-
microcarrier-grown endothelial cells
- PDGF:
-
platelet-derived growth factor
- PGI2 :
-
prostacyclin
- TCIPA:
-
tumor cell-induced platelet aggregation
- TXA2 :
-
thromboxane A2
- TXSI:
-
thromboxane A2 synthase inhibitor
- W256:
-
Walker 256 carcinosarcoma
- 125I-Udr:
-
5-[125I]-iododeoxyuridine.
References
Bastida E, Ordinas A, Giardina SL, Jamieson GA (1982) Differentiation of platelet aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase. Cancer Res 42: 4348–4352
Brain MC, Azzopardi JG, Baker LRI, Pinco GF, Roberts PD, Dacic JV (1970) Microangiopathic haemolytic anemia and mucin-forming adenocarcinoma. Br J Haematol 18: 183–190
Cavanaugh PG, Sloane BF, Bajkowski AS, Gasic GJ, Gasic TB, Honn KV (1983) Involvement of a cathepsin B-like cysteine proteinase in platelet aggregation induced by tumor cells and their shed membrane vesicles. Clin Exp Metastasis 1: 297–307
Dexter DL, Kowalski HM, Blazar HA, Fligiel A, Heppner GH (1978) Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 38: 3174–3179
Edwards RL, Rickles FR (1984) Hemostatic alterations in cancer patients. In: Honn KV, Sloane BF (eds) Hemostatic Mechanisms of Metastasis. Martinus Nijhoff, The Hague, pp 342–354
Gasic GJ (1984) Role of plasma, platelets and endothelial cells in tumor metastasis. Cancer Metastasis Rev 3: 99–116
Gasic GJ, Gasic TB, Stewart CC (1968) Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 61: 46–52
Grignani G, Pacehiarini L, Almasio P, Pagliasino M, Gamba G (1984) Activation of platelet prostaglandin biosynthesis pathway during neoplastic cell induced platelet aggregation. Thromb Res 34: 147–157
Hilgard P, Beyerle L, Hohage R, Hiemeyer V, Kubler M (1972) The effect of heparin on the initial phase of metastasis formation. Eur J Cancer 8: 347–352
Honn KV (1983) Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/ thromboxane A2 system. Clin Exp Metastasis 1: 103–114
Honn KV, Sloane BF (1983) Hemostatic Mechanisms and Metastasis. Martinus Nijhoff, The Hague
Honn KV, Cicone B, Skoff A (1981) Prostacyclin: a potent antimetastatic agent. Science 212: 1270–1272
Honn KV, Menter D, Cavanaugh PG, Neagos G, Moilanen D, Taylor JD, Sloane BF (1983a) A review of prostaglandins and the treatment of tumor metastasis. Acta Clin Belg 38: 53–67
Honn KV, Menter D, Moilanen D, Cavanaugh PG, Taylor JD, Sloane BF (1983b) Role of prostacyclin and thromboxanes in tumor cell-platelet-vessel wall interactions. In: McBrein DCH, Slater TF (eds) Protective Agents in Cancer. Academic Press, London, pp 57–59
Honn KV, Menter DG, Onoda JM, Taylor JD, Sloane BF (1984) Role of prostacyclin as a natural deterrent to hematogenous tumor metastasis. In: Nicolson GL, Milas L (eds) Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects. Raven, New York, pp 361–368
Honn KV, Onoda JM, Menter DG, Cavanaugh PG, Taylor JD, Crissman JD, Ryan RE, Sloane BF (1986) Possible strategies for antimetastatic therapy. In: Welch DR, Bhuyan BK, Liotta LA (eds) Cancer Metastasis. Experimental and Clinical Strategies. Alan R Liss, New York, pp 217–246
Honn KV, Menter DG, Onoda JM, Steinert BW, Diglio CA, Taylor JD, Sloane BF (1987) Tumor cell-platelet-endothelial cell interactions and prostaglandin metabolism. In: Samuelsson B, Paoletti R, Ramwell PW (eds) Advances in Prostaglandin, Thromboxane, and Leukotriene Research. Raven, New York, pp 977–981
Jamieson GA (1982) Interaction of Platelets and Tumor Cells. Alan R Liss, New York
Karniguian A, Simmons P, Legrand YJ, Moncada S, Caen JP (1982) A comparison of the inhibitory effect of prostacyclin and carbacyclin on platelet adhesion to collagen. Prostaglandins 24: 827–836
Laghi F, DiRoberto PF, Panici PB, Margariti PI, Scribano D, Cudillo L, Villani L, Bizzi B (1983) Coagulation disorders in patients with tumors of the uterus. Tumori 69: 349–353
Lipton A, Cano C, Leitzel K (1984) Mitogenic stimulation of tumor cells by platelet derived growth factors. In: Honn KV, Sloane BF (eds) Hemostatic Mechanisms and Metastasis. Martinus Nijhoff, The Hague, pp 266–281
Menter D, Neagos G, Dunn J, Palazzo R, Tchen TT, Taylor JD, Honn KV (1982) Tumor cell induced platelet aggregation: inhibition by prostacyclin, thromboxane A2 and phosphodiesterase inhibitors. In: Powles TJ, Bockman RS, Honn KV, Ramwell PW (eds) Prostaglandins and Cancer. Alan R Liss, New York, pp 809–814
Menter DG, Onoda JM, Taylor JD, Honn KV (1984) Effects of prostacyclin on tumor cell induced platelet agpegation. Cancer Res 44: 450–456
Menter DG, Hatfield JS, Harkins C, Sloane BF, Taylor JD, Crissman JD, Honn KV (1987) Tumor cell-platelet interactions in vitro and their relationship to in vivo arrest of hematogenously circulating tumor cells. Clin Exp Metastasis (in press)
Miner KM, Kawaguchi T, Uba GW, Nicolson GL (1982) Clonal drift of cell surface, melanogenic, and experimental metastatic properties of in vivo selected, brain meninges-colonizing murine B16 melanoma. Cancer Res 42: 4631–4638
Moncada S, Vane JR (1977) The role of prostacyclin in vascular tissue. Fed Proc 38: 66–71
Pearlstein E, Ambrogio C, Gasic G, Karpatkin S (1981) Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-l,5-pentanediyl)amide. Cancer Res 41: 4535–4539
Rickles FR, Edwards RL (1983) Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 62: 14–31
Rowland RN, Donovan MJ, Picciano PT, Kreutzer DL (1984a) Fibrin-mediated vascular injury: demonstration of vascular endothelial cell retraction in response to soluble fibrin-associated factors. J Exp Pathol 3: 217–240
Rowland FN, Donovan MJ, Picciano PT, Wilner GD, Kreutzer DL (1984b) Fibrin-mediated vascular injury. Identification of fibrin peptides that mediate endothelial cell retraction. Am J Pathol 117: 418–428
Sacchi A, Mauro F, Zupi G (1984) Changes of phenotypic characteristics of variants derived from Lewis lung carcinoma during long-term in vitro growth. Clin Exp Metastasis 2: 171–178
Salsbury J A (1975) The significance of the circulating cancer cell. Cancer Treat Rev 2: 55–72
Sindelar WR, Tralka TS, Ketcham AS (1975) Electron microaeopic observations on formation of pulmonary metastases. J Surg Res 18: 137–161
Sloane BF, Honn KV, Sadler JG, Turner WA, Kimpson JJ, Taylor JD (1982) Cathepsin B activity in B16 melanoma cells: a possible marker for metastatic potential. Cancer Res 42: 980–986
Talmadge JE, Meyers KM, Priener DJ, Starkey JR (1980) Role of NK cells in tumor growth and metastasis in beige mice. Nature 284: 622–624
Weiss L (1980) Cancer cell traffic from the lungs to the liver: an example of metastatic inefficiency. Int J Cancer 25: 385–392
Weiss L (1982) Metastatic inefficiency. In: Liotta LA, Hart IR (eds) Tumor Invasion and Metastasis. Martinus Nijhoff, The Hague, pp 81–98
Weiss L (1983) Overview of the metastatic cascade. In: Honn KV, Sloane BF (eds) Hemostatic Mechanisms of Metastasis. Martinus Nijhoff, The Hague pp 15–38
Weiss L, Dimitrov DS, Angelova M (1985) The hemodynamic destruction of intravascular cancer cells in relation to myocardial metastasis. Proc Natl Acad Sci USA 82: 5357–5341
Welch DR, Milas L, Tomasovic SP, Nicolson GL (1983) Heterogenous response and clonal drift of sensitivities of metastatic 13762F mammary adenocarcinoma clones to gamma radiation in vitro. Cancer Res 43: 6–10
Whittle BJR, Moncada S, Whiting F, Vane JR (1980) Carbacyclin-a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins 19: 605–627
Zacharski LR, Rickles FR, Henderson WG, Martin JF, Forman WB, van Eeckhoust JP, Cornell CJ, Forcier RJ (1982) Platelets and malignancy. Rationale and experimental design for the VA Cooperative Study of RA-233 in the treatment of cancer. Am J Clin Oncol 5: 593–609
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Honn, K.V., Menter, D.G., Steinert, B.W., Taylor, J.D., Onoda, J.M., Sloane, B.F. (1987). Analysis of Platelet, Tumor Cell and Endothelial Cell Interactions in Vivo and in Vitro. In: Garaci, E., Paoletti, R., Santoro, M.G. (eds) Prostaglandins in Cancer Research. Proceedings in Life Sciences. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71904-2_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-71904-2_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71906-6
Online ISBN: 978-3-642-71904-2
eBook Packages: Springer Book Archive